MX2019014027A - Uso de glutamina sintetasa para tratar hiperamonemia. - Google Patents
Uso de glutamina sintetasa para tratar hiperamonemia.Info
- Publication number
- MX2019014027A MX2019014027A MX2019014027A MX2019014027A MX2019014027A MX 2019014027 A MX2019014027 A MX 2019014027A MX 2019014027 A MX2019014027 A MX 2019014027A MX 2019014027 A MX2019014027 A MX 2019014027A MX 2019014027 A MX2019014027 A MX 2019014027A
- Authority
- MX
- Mexico
- Prior art keywords
- glutamine synthetase
- relates
- hyperammonemia
- protein
- treating hyperammonemia
- Prior art date
Links
- 102000005396 glutamine synthetase Human genes 0.000 title abstract 6
- 108020002326 glutamine synthetase Proteins 0.000 title abstract 6
- 206010020575 Hyperammonaemia Diseases 0.000 title abstract 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 238000009163 protein therapy Methods 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 229910021529 ammonia Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002516 radical scavenger Substances 0.000 abstract 1
- 238000007910 systemic administration Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
- C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención actual se refiere al uso de glutamina sintetasa como una terapia de proteínas (tal como terapia de proteínas de remplazo de enzima) para el tratamiento de hiperamonemia. En particular la invención se refiere a la administración sistémica de glutamina sintetasa. La glutamina sintetasa puede proporcionarse en una forma conjugada o en fusión, para incrementar la semivida en la circulación. También se proporciona una composición farmacéutica que comprende glutamina sintetasa. La invención también se refiere a los usos, métodos y composiciones que involucran una composición de la proteína glutamina sintetasa y un agente reductor de amoníaco, tal como un depurador de nitrógeno.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1708288.4A GB201708288D0 (en) | 2017-05-24 | 2017-05-24 | Use of glutamine synthetase for treating hyperammonemia |
GBGB1800867.2A GB201800867D0 (en) | 2018-01-19 | 2018-01-19 | Use of glutamine synthetase for treating hyperammonemia |
PCT/GB2018/051415 WO2018215780A1 (en) | 2017-05-24 | 2018-05-24 | Use of glutamine synthetase for treating hyperammonemia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019014027A true MX2019014027A (es) | 2020-08-03 |
Family
ID=62492675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019014027A MX2019014027A (es) | 2017-05-24 | 2018-05-24 | Uso de glutamina sintetasa para tratar hiperamonemia. |
Country Status (11)
Country | Link |
---|---|
US (4) | US20210145946A1 (es) |
EP (3) | EP4295904A3 (es) |
JP (3) | JP2020520677A (es) |
KR (1) | KR20200018488A (es) |
CN (2) | CN118105471A (es) |
AU (2) | AU2018272294B2 (es) |
BR (1) | BR112019024750A2 (es) |
CA (1) | CA3064352A1 (es) |
IL (1) | IL270817A (es) |
MX (1) | MX2019014027A (es) |
WO (1) | WO2018215780A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220218802A1 (en) * | 2018-09-28 | 2022-07-14 | Thoeris Gmbh | Use of glutamine synthetase for treating fatty liver disease |
CN110133287B (zh) * | 2019-05-22 | 2021-07-30 | 上海碧云天生物技术有限公司 | 蛋白抽提溶液及其应用 |
JP2023532939A (ja) | 2020-06-30 | 2023-08-01 | インダストリー-アカデミック コーオペレイション ファウンデーション キョンサン ナショナル ユニバーシティ | チロシンを有効成分として含むタンパク質内のチロシンのニトロ化による疾患の予防、改善または治療用組成物 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7590493B2 (en) | 2000-07-31 | 2009-09-15 | Ocimum Biosolutions, Inc. | Methods for determining hepatotoxins |
US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
US6451547B1 (en) * | 2001-04-25 | 2002-09-17 | Syn X Pharma | Process for differential diagnosis of Alzheimer's dementia and device therefor |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
AUPR805101A0 (en) | 2001-10-03 | 2001-10-25 | University Of New South Wales, The | A method of genetic screening using an amplifiable gene |
JP2003225093A (ja) | 2001-11-30 | 2003-08-12 | Sumitomo Pharmaceut Co Ltd | 軟骨障害マーカー及びその利用 |
US6875792B2 (en) | 2002-01-31 | 2005-04-05 | Mso Pharma Llc | Dosage form of L-Methionine S-Sulfoximine |
JP2003274963A (ja) | 2002-03-22 | 2003-09-30 | Japan Science & Technology Corp | 遺伝子組換え細胞株及びそれを用いた肝機能補助装置 |
US20050074865A1 (en) * | 2002-08-27 | 2005-04-07 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
WO2004060270A2 (en) | 2002-10-18 | 2004-07-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
WO2004106489A2 (en) | 2003-05-21 | 2004-12-09 | Divergence, Inc | Nematode GS-like sequences |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20070098702A1 (en) * | 2005-02-17 | 2007-05-03 | University Of Maryland, Baltimore | Recombinant protein polymer vectors for systemic gene delivery |
EP1752143A1 (en) | 2005-08-08 | 2007-02-14 | NewThera | Novel uses for drugs targeting glutamine synthetase |
DE602006020071D1 (de) | 2005-12-21 | 2011-03-24 | Univ Catholique Louvain | Isolierte leberstammzellen |
RU2362572C2 (ru) | 2007-07-17 | 2009-07-27 | Юрий Георгиевич Каминский | Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы |
WO2009134460A1 (en) * | 2008-04-29 | 2009-11-05 | Hyperion Therapeutics | Methods of treatment using ammonia-scavenging drugs |
EP2352821B1 (en) | 2008-09-08 | 2016-11-23 | Cellectis | Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof |
EP2575862A2 (en) * | 2010-05-28 | 2013-04-10 | Mind-Nrg Sa | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
WO2013020914A1 (en) * | 2011-08-10 | 2013-02-14 | Celares Gmbh | Peg-conjugated peptides |
EP2825641A4 (en) | 2012-03-12 | 2015-09-30 | Hanwha Chemical Corp | EXPRESSION VECTOR WITH A POLYNUCLEOTIDE CODING FOR A MODIFIED GLUTAMINE SYNTHETASE AND METHOD FOR PRODUCING A TARGET PROTEIN THEREFOR |
EP2674495A1 (en) | 2012-06-14 | 2013-12-18 | Sanofi | CHO expression system |
MX2014013566A (es) | 2014-11-07 | 2016-05-09 | Inst Nac De Ciencias Medicas Y Nutricion Salvador Zubiran | Terapia genica para tratar la hiperamonemia en la encefalopatia hepatica y en otras enfermedades del higado. |
JP6797117B2 (ja) | 2014-11-24 | 2020-12-09 | ユーシーエル ビジネス リミテッド | アンモニア降下療法を用いた肝星細胞活性化関連疾患の処置 |
CA2988930A1 (en) * | 2015-06-10 | 2016-12-15 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
EP3436576A4 (en) | 2016-03-30 | 2019-10-30 | Spark Therapeutics, Inc. | CELL LINE FOR THE PRODUCTION OF RECOMBINANT PROTEIN AND / OR A RECOMBINANT VIRAL VECTOR |
AU2017263454B2 (en) | 2016-05-11 | 2023-02-09 | Amgen Inc. | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors |
WO2018093331A1 (en) | 2016-11-16 | 2018-05-24 | Agency For Science, Technology And Research | Attenuated glutamine synthetase as a selection marker |
WO2019014652A1 (en) | 2017-07-13 | 2019-01-17 | Memphis Meats, Inc. | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CELL CULTURES USED IN FOOD PRODUCTION |
US11713468B2 (en) | 2017-08-02 | 2023-08-01 | Dna Twopointo Inc. | DNA vectors and elements for sustained gene expression in eukaryotic cells |
CN109988777A (zh) | 2017-12-29 | 2019-07-09 | 南京金斯瑞生物科技有限公司 | 谷氨酰胺合成酶基因以及应用 |
CN110714057A (zh) | 2018-07-11 | 2020-01-21 | 成都金洛克生物技术有限公司 | 用于检测外源基因整合和定位的通用型fish探针及其应用 |
CN109504709B (zh) | 2018-11-28 | 2020-07-24 | 上海安民生物技术有限公司 | 白蛋白启动子驱动的白蛋白表达载体 |
WO2020227206A1 (en) | 2019-05-07 | 2020-11-12 | Amgen Inc. | Vectors and expression systems for producing recombinant proteins |
-
2018
- 2018-05-24 EP EP23206416.2A patent/EP4295904A3/en active Pending
- 2018-05-24 AU AU2018272294A patent/AU2018272294B2/en active Active
- 2018-05-24 KR KR1020197038087A patent/KR20200018488A/ko not_active Application Discontinuation
- 2018-05-24 BR BR112019024750A patent/BR112019024750A2/pt unknown
- 2018-05-24 CA CA3064352A patent/CA3064352A1/en active Pending
- 2018-05-24 CN CN202410244176.5A patent/CN118105471A/zh active Pending
- 2018-05-24 US US16/616,884 patent/US20210145946A1/en active Pending
- 2018-05-24 EP EP22176864.1A patent/EP4119133A1/en active Pending
- 2018-05-24 WO PCT/GB2018/051415 patent/WO2018215780A1/en active Application Filing
- 2018-05-24 MX MX2019014027A patent/MX2019014027A/es unknown
- 2018-05-24 EP EP18728717.2A patent/EP3630077A1/en active Pending
- 2018-05-24 CN CN201880049768.4A patent/CN111093641A/zh active Pending
- 2018-05-24 JP JP2020515296A patent/JP2020520677A/ja active Pending
-
2019
- 2019-11-21 IL IL270817A patent/IL270817A/en unknown
-
2022
- 2022-06-03 US US17/832,562 patent/US11932885B2/en active Active
- 2022-06-03 US US17/832,564 patent/US20220401532A1/en active Pending
-
2023
- 2023-03-10 JP JP2023038030A patent/JP2023085301A/ja active Pending
- 2023-10-30 US US18/497,740 patent/US20240150746A1/en active Pending
-
2024
- 2024-02-20 AU AU2024201089A patent/AU2024201089A1/en active Pending
- 2024-02-26 JP JP2024026784A patent/JP2024059833A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN118105471A (zh) | 2024-05-31 |
JP2023085301A (ja) | 2023-06-20 |
US11932885B2 (en) | 2024-03-19 |
EP4295904A2 (en) | 2023-12-27 |
KR20200018488A (ko) | 2020-02-19 |
BR112019024750A2 (pt) | 2020-06-09 |
AU2018272294B2 (en) | 2024-05-23 |
US20240150746A1 (en) | 2024-05-09 |
IL270817A (en) | 2020-01-30 |
EP4119133A1 (en) | 2023-01-18 |
JP2024059833A (ja) | 2024-05-01 |
US20220401531A1 (en) | 2022-12-22 |
WO2018215780A1 (en) | 2018-11-29 |
AU2018272294A1 (en) | 2020-01-16 |
CN111093641A (zh) | 2020-05-01 |
AU2024201089A1 (en) | 2024-03-14 |
EP4295904A3 (en) | 2024-02-28 |
EP3630077A1 (en) | 2020-04-08 |
US20210145946A1 (en) | 2021-05-20 |
US20220401532A1 (en) | 2022-12-22 |
CA3064352A1 (en) | 2018-11-29 |
JP2020520677A (ja) | 2020-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
MX2017013983A (es) | Uso de agentes activos durante tratamientos quimicos. | |
PH12019501443A1 (en) | Benzooxazole derivatives as immunomodulators | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
MX2022002938A (es) | Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta). | |
PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
MX2019011219A (es) | Administracion rapida y controlada de composiciones con efectos sequito restaurados. | |
MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
MX2021008610A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
SG10201902664RA (en) | Combination therapy for treating cancer | |
GB2541835A (en) | Multivesicular liposome formulations of tranexamic acid | |
WO2017218981A3 (en) | Compositions and methods for reducing ocular neovascularization | |
MX2019014027A (es) | Uso de glutamina sintetasa para tratar hiperamonemia. | |
MX2018009173A (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash). | |
MX2019008999A (es) | Composicion inyectable para prevenir la perdida del pelo o estimular el crecimiento del pelo. | |
MX2021001376A (es) | Carboxamidas como inhibidores de proteasa específicos de ubiquitina. | |
PH12016501527A1 (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
MX2021004598A (es) | Inhibidores selectivos de rgmc y el uso de los mismos. | |
EP4331670A3 (en) | Magnesium-containing oxytocin formulations and methods of use | |
MX2019009952A (es) | Formulaciones de evolocumab de baja viscosidad y alta concentracion y metodos de elaboracion de las mismas. | |
WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
MX2021007453A (es) | Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo. | |
WO2018085574A3 (en) | Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof |